SpliSense Secures $28.5 Million in Series B Financing
Round includes up to $8.4 million investment by the Cystic Fibrosis Foundation
Funds will be used to advance the Company's mRNA-altering pipeline for the treatment of cystic fibrosis and other genetic pulmonary diseases
JERUSALEM, May 13, 2021 -- (He... Biopharmaceuticals, Venture Capital SpliSense, Cystic Fibrosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 13, 2021 Category: Pharmaceuticals Source Type: news
Antimicrobial prescribing: nebulised liposomal amikacin - evidence summary [ES36], NICE (published 12th May 2021)
This concludes nebulised liposomal amikacin may be an option for treating non-tuberculous mycobacterial lung infections caused by Mycobacterium avium complex in combination with other antimicrobial agents in adults with limited treatment options& who do not have cystic fibrosis. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - May 13, 2021 Category: Consumer Health News Source Type: news
Novel nanotech improves cystic fibrosis antibiotic by 100,000-fold
(University of South Australia) World-first nanotechnology developed by the University of South Australia could change the lives of thousands of people living with cystic fibrosis (CF) as groundbreaking research shows it can improve the effectiveness of the CF antibiotic Tobramycin, increasing its efficacy by up to 100,000-fold. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - May 13, 2021 Category: Biology Source Type: news
New study determines cystic fibrosis therapy is safe and effective for young children
(Children's Hospital Colorado) Children ages two to five who have the most common form of cystic fibrosis have not had any modulator treatments available to them until recently. A new study authored by researchers at Children's Hospital Colorado and published May 6, 2021, in Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 7, 2021 Category: International Medicine & Public Health Source Type: news
Molecular analysis identifies key differences in lungs of cystic fibrosis patients
A team of researchers from UCLA, Cedars-Sinai and the Cystic FibrosisFoundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis.The catalog,described today in the journal Nature Medicine, reveals new subtypes of cells and illustrates how the disease changes the cellular makeup of the airways. The findings could help scientists in their search for specific cell types that represent prime targets for genetic and cell therapies for cystic fibrosis.“This new research has provided us with valuable insights into the cellular makeup of both healthy and ...
Source: UCLA Newsroom: Health Sciences - May 7, 2021 Category: Universities & Medical Training Source Type: news
Molecular analysis identifies key differences in lungs of cystic fibrosis patients
(Cedars-Sinai Medical Center) A team of researchers from UCLA, Cedars-Sinai and the Cystic Fibrosis Foundation has developed a first-of-its-kind molecular catalog of cells in healthy lungs and the lungs of people with cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 6, 2021 Category: International Medicine & Public Health Source Type: news
Multi-drug resistant infection about to evolve within cystic fibrosis patients
(University of Cambridge) Scientists have been able to track how a multi-drug resistant organism is able to evolve and spread widely among cystic fibrosis patients - showing that it can evolve rapidly within an individual during chronic infection. The researchers say their findings highlight the need to treat patients with Mycobacterium abscessus infection immediately, counter to current medical practice. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - April 29, 2021 Category: Infectious Diseases Source Type: news
Bypassing broken genes
(Penn State) A new approach to gene editing using the CRISPR/Cas9 system bypasses disease-causing mutations in a gene, enabling treatment of genetic diseases linked to a single gene, such as cystic fibrosis, certain types of sickle cell anemia, and other rare diseases. The method involves inserting a new, fully functional copy of the gene that displaces the mutated gene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 21, 2021 Category: International Medicine & Public Health Source Type: news
Study aims to improve health of patients with CF across their increasing lifespan
(Medical College of Georgia at Augusta University) People with cystic fibrosis are living better and longer, and now investigators want to further enhance quality and longevity by better understanding the role of nutrition, body composition and exercise in their health across an increasing lifespan. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2021 Category: International Medicine & Public Health Source Type: news
Three - Drug Regimen Treats Cystic Fibrosis in Younger Children
Elexacaftor/tezacaftor/ivacaftor well tolerated in children aged 6 through 11 years with cystic fibrosis and at least one F508del - CFTR allele (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - April 14, 2021 Category: Respiratory Medicine Tags: Family Medicine, Pediatrics, Pharmacy, Pulmonology, Journal, Source Type: news
Three-Drug Regimen Treats Cystic Fibrosis in Younger Children
WEDNESDAY, April 14, 2021 -- The safety and efficacy of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) for the treatment of cystic fibrosis with at least one F508del-CFTR allele in children aged 6 to 11 years are consistent with the results reported... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 14, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Media News - April 13, 2021 Category: Pharmaceuticals Source Type: news
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
● Xolair for self-injection offers healthcare providers and appropriate patients another administration option for more flexibility in managing their treatmentBasel, 13 April 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved the company ’s supplemental Biologics License Application for Xolair® (omalizumab) prefilled syringe for self-injection across all approved U.S. indications.1 Xolair is the only FDA-approved biologic designed to target and block immunoglobulin E (IgE) for the treatment of moderate to severe persistent allergic asthma, chronic...
Source: Roche Investor Update - April 13, 2021 Category: Pharmaceuticals Source Type: news
< a href= " /news-events/nih-research-matters/sweat-sticker-diagnosing-cystic-fibrosis " > “Sweat sticker” for diagnosing cystic fibrosis < /a >
Researchers created a “sweat sticker” for measuring chloride concentrations in sweat, a sign of cystic fibrosis. (Source: NIH Research Matters from the National Institutes of Health (NIH))
Source: NIH Research Matters from the National Institutes of Health (NIH) - April 13, 2021 Category: Consumer Health News Source Type: news
Bioengineer wins NIH grant to attack cystic fibrosis
(Rice University) Rice University chemical and biomolecular engineer Xue Sherry Gao wins a prestigious National Institutes of Health R01 grant to develop personalized gene editing techniques for cystic fibrosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 8, 2021 Category: International Medicine & Public Health Source Type: news
